Candel Therapeutics (CADL) shares were down over 24% in recent trading on Tuesday after the company said three of seven patients with borderline resectable pancreatic ductal adenocarcinoma, or PDAC, who received CAN-2409 were still alive at the time of data cut-off.
The phase 2 study evaluated CAN-2409 plus valacyclovir together with standard-of-care chemoradiation, followed by resection, in patients with borderline resectable PDAC, according to the company.
The data cutoff date was Feb. 20 and median overall survival after enrollment was 31.4 months in the CAN-2409 group compared with 12.5 months in the control group.
Median survival after progression was 21.2 months in the CAN-2409 arm versus 7.2 months in the control arm, Candel added.
Price: 8.28, Change: -2.68, Percent Change: -24.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。